A new study published in the journal of Cardiovascular Revascularization Medicine revealed that in patients with complex left ...

Dual anti-platelet therapy remains a cornerstone of the treatment for coronary artery disease. When choosing a second anti-platelet, ticagrelor remains a principal agent after the recent PLATO trial ...

A number of trials show aspirin is not effective compared with a placebo in primary prevention of stroke, heart attack or death from vascular disease ...

The high-risk angioplasty was performed at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, on a patient diagnosed with severe multi-vessel coronary artery disease and a critically low ejection ...

For women with severe CAD, percutaneous coronary intervention is associated with increased risk for MACCE and all-cause mortality compared with CABG.

A first-in-human percutaneous aorto-coronary bypass procedure, dubbed "VECTOR," was used to prevent coronary obstruction ...

Nyrada shares have hit a new record high after the company received approval to go ahead with a clinical trial in heart ...

A news release from the hospital Thursday, announced the lab received reaccreditation for Percutaneous Coronary Intervention ...

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical ...